Bolt Biotherapeutics reports 2021 results; cash $271.6M, BDC-1001 on track for RP2D in 2022

Bolt Biotherapeutics, Inc.

Cash, cash equivalents, and marketable securities $271.6M at Dec 31, 2021 vs $22.8M at end 2020; runway into 2024.
Collaboration revenue $1.3M for FY 2021 from Genmab R&D collaboration (vs $0.2M in 2020).
R&D expenses $75.7M, G&A $18.4M; operating loss $92.8M for FY 2021.
BDC-1001 (HER2) Phase 1/2 on track for recommended Phase 2 dose in 2022; Opdivo combo arm dosed first patient Dec 2021.
Preclinical data on BDC-2034, BDC-3042, and PD-L1 ISAC to be presented at AACR 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.